Prakt. lékáren. 2020; 16(2): 67-73 | DOI: 10.36290/lek.2020.010

Antihistamines indicated for systemic and topical treatment

Veronika Kunešová
II. chirurgická klinika, Centrum pro cévní onemocnění, Fakultní nemocnice u sv. Anny v Brně a Lékařská fakulta Masarykovy Univerzity, Brno

Antihistamines represent a category of drugs that inhibit the binding of histamine to its H1 receptors and thereby affect its local action, do not block or reduce histamine release. Antihistamines are considered the first line of choice for allergic reactions, but their clinical potential is much broader. Their main indication is allergic rhinitis, allergic conjunctivitis, urticaria, angioedema, allergic rash or anaphylaxis. This group of drugs belongs to the category of therapeutics used in clinical practice for more than half a century and yet in some drugs we do not know their pharmacokinetic and dynamic parameters in details. In many cases, the choice of a given antihistamine is only an empirical choice. However, it is clear that not every antihistamine is suitable for every individual patient. The choice of the right substance from the group of antihistamines is influenced by the desired resultant effect, the particular problem, age, health condition and possible occurrence of other patient co-morbidities. The degree of effectiveness of antihistamine therapy for a given problem may also be modulated by the route of administration. Therefore, drugs from this pharmacotherapeutic group are available in different dosage forms, both prescription and OTC.

Keywords: allergy, topical antihistamines, systemic antihistamines, indications of antihistamines.

Published: June 22, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kunešová V. Antihistamines indicated for systemic and topical treatment. Praktické lékárenství. 2020;16(2):67-73. doi: 10.36290/lek.2020.010.
Download citation

References

  1. Akdis CA, Simons FER. Histamine receptors are hot in immunopharmacology. Eur J Pharmacol. 2006; 533: 69-76. Go to original source... Go to PubMed...
  2. Simons FER. Advances in H1-antihistamines. N Engl J Med. 2004; 351: 2203-2217. Go to original source...
  3. Timmerman H. Histamine receptors in the CNS. Pharm Weekbl Sci 1989; 11: 146-150. Go to original source... Go to PubMed...
  4. Triggiani M, et al. Effects of histamine on human inflammatory cell activation. Clin Exp All Rev 2002; 2: 89-94. Go to original source...
  5. Simons FE. Advances in H1-antihistamines. N Engl J Med 2004; 351(21): 2203-2217. Go to original source... Go to PubMed...
  6. Yanai K, et al. Safety considerations in the management of allergic diseases: focus on antihistamines. Curr Med Res Opin 2012; 28(4): 623-642. Go to original source...
  7. Simons F.E., Simons K.J. The pharmacology and use of H1-receptor‑antagonist drugs. N Engl J Med 1994; 330(23): 1663-1670. Go to original source... Go to PubMed...
  8. Hu WW, Chen Z. Role of histamine and its receptors in cerebral ischemia. ACS Chem Neurosci 2012; 3(4): 238-247. Go to original source... Go to PubMed...
  9. Estelle F, Simons R. H1-receptor antagonists: safety issues. Ann Allergy Asthma Immunol 1999; 83(5): 481-488. Go to original source... Go to PubMed...
  10. White MV, Kaliner MA. Histamine in allergic diseases. In: Simons FER (ed). Histamine and H1-receptor antagonists in allergic disease. New York: Marce Dekker 1996; 61-90.
  11. Malinowska B, Godlewski G, Schlicker E. Histamine H3-receptors - general characterisation and their function in the cardiovascular system. J Physiol Pharmacol 1998; 49: 191-211. Go to PubMed...
  12. Oda A., Morikawa AN, et al. Molecular cloning and characterisation of a novel type of histamine receptor preferentially expressed in leucocytes. J Biol Chem 2000; 275: 36781-36786. Go to original source... Go to PubMed...
  13. Pawankar R, et al. World Allergy Organization - White Book on Allergy, 2011.
  14. WAO. World Allergy Organization. 2012; http://www.worldallergy.org/index.php?url=index.html.
  15. CIOMS. Council for International Organizations of Medical Science. 2012; http://www.cioms.ch/index.php/2012-06-07-19-16-08/membership
  16. Bousquet J, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) Allergy, 2008; 63(86): 8-160. Go to original source...
  17. Seberová E. Antihistaminika v léčbě alergických chorob. Remedia 2003; 13: 49-56.
  18. Lexi‑Comp, O. Lexi‑Comp Online Database. 2012; www.lexi.com
  19. Administration FD. FDA. 2012; www.fda.gov
  20. Holgate ST, Canonica GW, Simons FER, Taglialatela M, Tharp M, Timmerman H, Yanai K: Consensus Group on New‑Generation Antihistamines (CONGA): present status and recommendations. Clin Exp Allergy. 2003; 33: 1305-1324. Go to original source... Go to PubMed...
  21. Simons FE. Comparative pharmacology of H1 antihistamines: clinical relevance. Am J Med. 2002; 113(9 A): 38-46. Go to original source... Go to PubMed...
  22. Simons FE. H1-Antihistamines: more relevant than ever in the treatment of allergic disorders. J Allergy Clin Immunol. 2003; 112: 42-52. Go to original source...
  23. Timmerman H. Factors involved in the incidence of CNS effects of H1-blockers. In: Church NK, Rihoux JP. Therapeutics index of antihistamines. New York: Hogrefe & Hubers, 1992; 19-31.
  24. Simons FER, et al. Central nervous system effects of H1-receptor antagonists in the elderly. Ann Allergy Asthma Immunol 1999; 82: 157-160. Go to original source...
  25. Fromer LM, Ortiz GR, Dowdee AM. Assessment of Patient Attitudes About Mometasone Furoate Nasal Spray: The Ease‑of‑Use Patient Survey. The World Allergy Organization Journal 2008; 1(9): 156-159. Go to original source... Go to PubMed...
  26. https://www.drugs.com/international/dimetindene.html
  27. https://web.archive.org/web/20180913201213/http://www.wikigenes.org/
  28. Janssens PP, Howarth PH. The antihistamines of the nineties. Clin Rev Allergy 1993; 11: 111-153. Go to original source...
  29. Hindmarch I, Johnson S, Meadows R, Kirkpatrick T, Shamsi Z. The acute and sub‑chronic effects of levocetirizine, cetirizine, loratadine, promethazine and placebo on cognitive function, psychomotor performance, and weal and flare. Curr Med Res Opin. 2001; 17: 241-255. Go to original source... Go to PubMed...
  30. Shamsi Z, Hindmarch I. Sedation and antihistamines: a review of inter‑drug differences using proportional impairment ratios. Hum Psychopharmacol Clin Exp. 2000; 15(1): 3-30. Go to original source...
  31. Casale TB, Blaiss MS, Gelfand E, Gilmore T, Harvey PD, et al. First do no harm: managing antihistamine impairment in patients with allergic rhinitis. J Allergy Clin Immunol 2003; 111: 835-842. Go to original source... Go to PubMed...
  32. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001; 108: 147-334. Go to original source... Go to PubMed...
  33. Camelo‑Nunes IC. New antihistamines: a critical view. Jornal de Pediatria 2006; 82(5): 173-180. Go to original source...
  34. ETAC Study Group, First Results of ETAC. Ped Allergy Med 1998; 9: 116-124. Go to original source...
  35. Barbey JT, Anderson M, Ciprandi G, et al. Cardiovascular safety of second generation antihistamines. Em J Rhinol 1999; 13: 235-243. Go to original source... Go to PubMed...
  36. Estelle F, Simon R, Simons KJ. H1 antihistamines: current status and future directions. World Allergy Organ J. 2008; 1(9): 145-155. Go to original source...
  37. White MV, Slater JE, Kaliner MA. Histamine and asthma. Am Rev Respir Dis 1987; 135: 1165-1176.




Pharmacy for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.